Table 2. Univariate and Multivariate Analyses of Prognostic Factorsa.
| Prognostic Factor | No. | Survival | |||
|---|---|---|---|---|---|
| Univariate | Multivariable | ||||
| HR (95% CI) | P Value | HR (95% CI) | P Value | ||
| Treatment | |||||
| NACT alone | 167 | 1 [Reference] | 1 [Reference] | ||
| NACT plus RHT | 162 | 0.73 (0.54-0.98) | .04 | 0.70 (0.52-0.95) | .02 |
| Age, y | |||||
| 18-40 | 88 | 1 [Reference] | ND | ||
| 41-70 | 241 | 0.97 (0.69-1.37) | .87 | ND | |
| Sex | |||||
| Men | 182 | 1 [Reference] | ND | ||
| Women | 147 | 0.85 (0.63-1.16) | .31 | ND | |
| Grade | |||||
| G3 | 176 | 1 [Reference] | 1 [Reference] | ||
| G2 | 153 | 0.68 (0.50-0.92) | .01 | 0.69 (0.51-0.94) | .02 |
| Tumor size, cm | |||||
| >12.0 | 130 | 1 [Reference] | 1 [Reference] | ||
| 5.0-12.0 | 199 | 0.63 (0.47-0.86) | .003 | 0.62 (0.46-0.84) | .002 |
| Presentation of tumor | |||||
| Recurrent | 37 | 1 [Reference] | ND | ||
| Primary | 157 | 0.62 (0.40-0.95) | .03 | ND | |
| Prior surgery | 135 | 0.42 (0.27-0.67) | <.001 | ND | |
| Site | |||||
| Nonextremity | 186 | 1 [Reference] | ND | ||
| Extremity | 143 | 0.45 (0.33-0.63) | <.001 | ND | |
Abbreviations: HR, hazard ratio; NACT neoadjuvant doxorubicin, ifosfamide, and etoposide chemotherapy; ND, no data; RHT, regional hyperthermia.
a
The analyses of subgroups (treatment, age, sex, grade, tumor size) were prespecified and stratified to tumor presentation and site. The univariate HR estimates for the stratification variables (tumor presentation and site) are given; HRs for stratification variables in multivariate analyses cannot be calculated.